腹腔镜下卵巢癌减灭术联合化疗治疗卵巢癌的疗效观察

doi:10.3969/j.issn.1000-8535.2021.03.009

广州医药 ›› 2021, Vol. 52 ›› Issue (3): 45-47.DOI: 10.3969/j.issn.1000-8535.2021.03.009

腹腔镜下卵巢癌减灭术联合化疗治疗卵巢癌的疗效观察

王帅, 文仲勇, 李莉芳, 王洪燕, 黄浩

佛山市南海区人民医院妇科(佛山 528000)

收稿日期:2021-01-20 发布日期:2021-11-24
通讯作者: 黄浩,E-mail:wangqww87@163.com

Laparoscopic ovarian cancer reduction combined with chemotherapy in the treatment of ovarian cancer

WANG Shuai, WEN Zhongyong, LI Lifang, WANG Hongyan, HUANG Hao

Department of Gynecology, Nanhai District People's Hospital, Foshan 528000,China

Received:2021-01-20 Published:2021-11-24

摘要/Abstract

摘要： 目的探讨腹腔镜下卵巢癌减灭术联合化疗治疗卵巢癌的疗效。方法选取2018年2月—2020年2月我院收治的68例卵巢癌患者,随机分为研究组和对照组各34例,对照组给予腹腔镜下卵巢癌减灭术,研究组给予腹腔镜下卵巢癌减灭术联合化疗。观察分析两组患者近期疗效、不良反应发生率、生存率以及相关手术情况等。结果研究组近期疗效优于对照组(P＜0.05);研究组术后1年生存率高于对照组(P＜0.05),且并发症发生率低于对照组(P＜0.05);研究组理想减灭率优于对照组(P＜0.05),且腹水量及术中出血量少于对照组(P＜0.05),手术时间短于对照组(P＜0.05)。结论减灭术联合化疗治疗卵巢癌可有效增强治疗疗效,降低多种化疗不良反应发生的可能性,并能使生存率得到进一步提升,可推广应用。

关键词: 腹腔镜下卵巢癌减灭术, 联合化疗, 卵巢癌, 疗效

Abstract: Objective To investigate the efficacy of laparoscopic ovarian cancer reduction combined with chemotherapy in the treatment of ovarian cancer. Methods A total of 68 ovarian cancer patients admitted to our hospital from February 2018 to February 2020 were randomly divided into study group and control group, 34 cases each. The control group was given laparoscopic ovarian cancer reduction surgery, while the study group was given laparoscopic ovarian cancer reduction surgery combined with chemotherapy. The short-term efficacy, incidence of adverse reactions, survival rate and related operation of the two groups were observed and analyzed. Results The short-term efficacy of the study group was better than that of the control group (P<0.05). The 1-year postoperative survival rate of the study group was higher than that of the control group (P<0.05), and the incidence of complications was lower than that of the control group (P<0.05). The ideal reduction rate of the study group was better than that of the control group (P<0.05), and the amount of abdominal water and intraoperative blood loss was less than that of the control group (P<0.05), and the operation time was shorter than that of the control group (P<0.05). Conclusion Laparoscopic ovarian cancer reduction combined with chemotherapy can effectively enhance the therapeutic effect, reduce the possibility of multiple adverse reactions of chemotherapy, and further improve the survival rate, which can be popularized and applied.

Key words: Laparoscopic ovarian cancer reduction, Combination chemotherapy, Ovarian cancer, Curative effect

王帅, 文仲勇, 李莉芳, 王洪燕, 黄浩. 腹腔镜下卵巢癌减灭术联合化疗治疗卵巢癌的疗效观察[J]. 广州医药, 2021, 52(3): 45-47.

WANG Shuai, WEN Zhongyong, LI Lifang, WANG Hongyan, HUANG Hao. Laparoscopic ovarian cancer reduction combined with chemotherapy in the treatment of ovarian cancer[J]. Guangzhou Medical Journal, 2021, 52(3): 45-47.

参考文献

[1] 贾慧珣,李俊,史庭燕.晚期卵巢癌中间型瘤体减灭术+腹腔热灌注化疗对比单纯中间型瘤体减灭术研究解读[J]. 中国癌症杂志, 2018,28(10):780-786.
[2] 柳禹,曹莉莉,周莉,等. 晚期上皮性卵巢癌经腹腔镜和开腹的初次肿瘤细胞减灭术或中间型减瘤术的临床对比研究[J]. 实用妇产科杂志, 2020, 36(4):298-302.
[3] 张珏,李鑫宝,姬忠贺,等. 倾向性评分匹配评估肿瘤细胞减灭术联合腹腔热灌注化疗治疗晚期卵巢癌的疗效[J]. 中国肿瘤临床, 2019,46(19):994-998.
[4] 王爱红, 赵菊梅, 杜娟,等. 腹腔热灌注化疗联合腹部射频热疗对老年晚期卵巢癌患者的疗效分析[J]. 中国免疫学杂志, 2018,34(4):583-588.
[5] SHUKUNA M I, KUROKAWA T,KUBO M, et al. Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin[J]. Tumori J,1999, 85(4):297-298.
[6] 庞丽,王蕾,魏茜雪.上皮性卵巢癌患者血小板增多对行二次肿瘤细胞减灭术预后影响[J]. 中华肿瘤防治杂志,2019,26(7):504-507.
[7] 张国楠,刘红,石宇.晚期卵巢上皮性癌广泛性腹膜切除术的理论基础与临床应用价值[J]. 中华妇产科杂志,2019,54(6):417-420.
[8] 周美英,陈晓红.紫杉醇与顺铂腹腔热灌注化疗治疗晚期卵巢癌疗效及对免疫功能影响[J]. 中华肿瘤防治杂志,2019,26(S1):115117.
[9] 刘帛岩,何长征,王玉峰,等. 肿瘤细胞减灭术联合腹腔热灌注化疗对结肠癌与直肠癌腹膜转移的远期疗效比较[J]. 解放军医学杂志, 2020, 45(1):79-83.
[10] SHIVAPPA N, JAMES RHÉBERT, ROSATO V, et al. Dietary inflammatory index and ovarian cancer risk in a large Italian case-control study[J]. Nutrition, 2018, 27(7):78-82.
[11] 凌小婷,徐国才,林荣春,等. 晚期卵巢癌腹腔化疗联合静脉化疗用于新辅助化疗Ⅰ期临床试验研究[J]. 中国实用妇科与产科杂志, 2019, 35(12):1345-1349.
[12] 陈丽佳,渠红,武珊珊,等. 康艾注射液联合DC化疗方案对卵巢癌晚期患者疾病控制率及中位生存期的影响[J]. 中国地方病防治杂志, 2018, 33(1):101-103.
[13] 刘雅坤,马静,王影.洛铂腹腔化疗联合紫杉醇对老年中晚期卵巢癌患者免疫功能及生存的影响[J]. 中国老年学杂志, 2020,40(18):50-53.
[14] 李丙森,孙夷平,刘虎,等. 白蛋白结合型紫杉醇联合贝伐单抗治疗中老年复发转移性卵巢癌的疗效及对患者生存质量的影响[J]. 中国老年学杂志, 2018, 38(10):2358-2360.
[15] SHI B, ZHANG Z Y, JIN Q Q, et al. Selective tracking of ovarian-cancer-specific γ-glutamyltranspeptidase using a ratiometric two-photon fluorescent probe[J]. J Mater ChemB, 2018, 6(45):7439-7443.

腹腔镜下卵巢癌减灭术联合化疗治疗卵巢癌的疗效观察

Laparoscopic ovarian cancer reduction combined with chemotherapy in the treatment of ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	骆超锋, 梁叠锋, 关国宏. 瑞格列奈联合胰岛素治疗2型糖尿病临床疗效及对患者血糖水平的影响[J]. 广州医药, 2021, 52(4): 65-67.
[2]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[3]	司徒宝珠. MP-SAT作为支原体肺炎患儿疗效监测指标的可行性分析[J]. 广州医药, 2021, 52(1): 87-91.